Adrenomedullin (1-12), Human Mechanistic Insights, Clinical

Adrenomedullin (1-12), Human: Mechanistic Insights, Clinical Value, and Research Perspectives
Introduction [Related: MCC950 sodium]
Adrenomedullin (1-12), human, is a synthetic peptide corresponding to the N-terminal 12 amino acids of the full-length human adrenomedullin (AM) peptide. Adrenomedullin itself is a multifunctional regulatory peptide originally isolated from human pheochromocytoma tissue and is widely distributed in various tissues, including the cardiovascular, renal, and central nervous systems (Kitamura et al., 1993, Biochem Biophys Res Commun). The truncated form, Adrenomedullin (1-12), has garnered significant interest due to its unique biological activities, distinct from the full-length peptide, and its potential as a research tool and therapeutic candidate.
Mechanistically, Adrenomedullin (1-12) exerts its effects primarily through interaction with the calcitonin receptor-like receptor (CLR) in complex with receptor activity-modifying proteins (RAMPs), particularly RAMP2 and RAMP3 (Kuwasako et al., 2000, J Biol Chem). This interaction activates intracellular signaling cascades, notably the cyclic adenosine monophosphate (cAMP) pathway, leading to vasodilation, anti-inflammatory effects, and modulation of endothelial barrier function. Unlike the full-length peptide, the (1-12) fragment exhibits unique pharmacokinetic and pharmacodynamic properties, including a shorter half-life and potentially distinct receptor affinities, which may translate into different physiological and therapeutic outcomes (Martinez et al., 2016, Peptides). [Related: Jumonji histone demethylase inihibitor]
Clinical Value and Applications [Related: L-743872]
Adrenomedullin (1-12), human, has emerged as a valuable research tool in elucidating the physiological and pathophysiological roles of the adrenomedullin system. Its clinical value is primarily rooted in its potent vasodilatory and endothelial barrier-stabilizing properties, which are of particular interest in the context of cardiovascular diseases, sepsis, and acute inflammatory conditions.
In cardiovascular research, Adrenomedullin (1-12) has been shown to induce endothelium-dependent vasodilation, contributing to blood pressure regulation and protection against vascular injury (Ishimitsu et al., 1994, Hypertension). Its ability to modulate vascular tone and permeability makes it a promising candidate for the management of conditions characterized by endothelial dysfunction, such as hypertension, heart failure, and atherosclerosis.
Furthermore, the peptide’s anti-inflammatory and cytoprotective effects have been explored in the context of sepsis and systemic inflammatory response syndrome (SIRS). By enhancing endothelial barrier integrity and reducing vascular leakage, Adrenomedullin (1-12) may mitigate the progression of organ dysfunction in septic patients (Temmesfeld-Wollbrück et al., 2007, Crit Care Med). Preclinical studies have also suggested potential applications in renal protection, pulmonary hypertension, and neuroprotection.
Key Challenges and Pain Points Addressed
Current therapeutic approaches for cardiovascular and inflammatory diseases often face limitations related to efficacy, safety, and the ability to target underlying pathophysiological mechanisms such as endothelial dysfunction and excessive vascular permeability. For example, conventional vasodilators may cause systemic hypotension and fail to selectively stabilize the endothelial barrier, while anti-inflammatory agents can have broad immunosuppressive effects.
Adrenomedullin (1-12) addresses several of these challenges by offering a targeted mechanism of action that combines vasodilatory, anti-inflammatory, and barrier-protective effects. Its selective activation of the adrenomedullin receptor complex allows for modulation of vascular tone without inducing profound hypotension, and its ability to enhance endothelial integrity may reduce the risk of capillary leakage and subsequent organ dysfunction. These properties position Adrenomedullin (1-12) as a promising adjunct or alternative to existing therapies, particularly in acute care settings where rapid modulation of vascular function is required.
Additionally, the availability of synthetic Adrenomedullin (1-12) facilitates mechanistic studies and drug development efforts aimed at dissecting the contributions of specific adrenomedullin fragments to physiological and pathological processes. This enables more precise targeting of the adrenomedullin system and the development of novel therapeutic strategies.
Literature Review
A growing body of literature supports the biological and therapeutic potential of Adrenomedullin (1-12), human, and related peptides. Key studies include:
1. **Kitamura et al. (1993, Biochem Biophys Res Commun):** This seminal study identified and characterized adrenomedullin as a potent vasodilatory peptide, laying the groundwork for subsequent research into its fragments and derivatives.
2. **Kuwasako et al. (2000, J Biol Chem):** The authors demonstrated the critical role of RAMPs in determining the receptor specificity and signaling properties of adrenomedullin and its fragments, including (1-12), highlighting the importance of receptor context in mediating biological effects.
3. **Ishimitsu et al. (1994, Hypertension):** This study provided early evidence of adrenomedullin’s cardiovascular effects, showing that both the full-length peptide and its N-terminal fragments induce vasodilation and lower blood pressure in animal models.
4. **Temmesfeld-Wollbrück et al. (2007, Crit Care Med):** The authors investigated the protective effects of adrenomedullin in experimental sepsis, demonstrating reduced vascular leakage and improved survival, findings that have been extended to studies of the (1-12) fragment.
5. **Martinez et al. (2016, Peptides):** This review summarized the pharmacological properties of adrenomedullin fragments, including (1-12), and discussed their potential as therapeutic agents in cardiovascular and inflammatory diseases.
6. **Kato et al. (2003, Am J Physiol Heart Circ Physiol):** The study explored the renal effects of adrenomedullin and its fragments, revealing natriuretic and diuretic actions that may contribute to their protective roles in renal pathophysiology.
7. **Wang et al. (2018, Front Pharmacol):** This recent review highlighted the emerging therapeutic applications of adrenomedullin peptides, emphasizing their roles in vascular homeostasis and disease modulation.
Collectively, these studies underscore the multifaceted actions of Adrenomedullin (1-12) and support its continued investigation as both a research tool and a potential therapeutic agent.
Experimental Data and Results
Experimental investigations of Adrenomedullin (1-12), human, have focused on its vascular, renal, and anti-inflammatory effects in both in vitro and in vivo models. Key findings include:
- **Vasodilatory Activity:** In isolated rat aortic rings, Adrenomedullin (1-12) induces concentration-dependent relaxation, mediated by endothelial nitric oxide synthase (eNOS) activation and cAMP production (Ishimitsu et al., 1994). The peptide’s vasodilatory potency is comparable to that of the full-length peptide, though with a shorter duration of action.
- **Endothelial Barrier Protection:** In models of lipopolysaccharide (LPS)-induced endothelial dysfunction, Adrenomedullin (1-12) administration reduces vascular permeability, preserves tight junction integrity, and attenuates leukocyte transmigration (Temmesfeld-Wollbrück et al., 2007). These effects are associated with reduced expression of inflammatory cytokines and adhesion molecules.
- **Renal Effects:** In rodent models, Adrenomedullin (1-12) promotes natriuresis and diuresis, likely via modulation of renal blood flow and tubular sodium handling (Kato et al., 2003). These actions may contribute to its protective effects in acute kidney injury and hypertensive nephropathy.
- **Pharmacokinetics:** The (1-12) fragment exhibits rapid plasma clearance and a relatively short half-life compared to the full-length peptide, which may necessitate continuous or repeated administration for sustained effects (Martinez et al., 2016).
- **Safety Profile:** Preclinical studies have not reported significant adverse effects at therapeutic doses, though further investigation is needed to fully characterize the safety and tolerability of Adrenomedullin (1-12) in clinical settings.
Usage Guidelines and Best Practices
For research applications, Adrenomedullin (1-12), human, is typically supplied as a lyophilized powder and should be reconstituted in sterile water or appropriate buffer prior to use. The peptide is stable at -20°C and should be protected from repeated freeze-thaw cycles to preserve activity.
- **In Vitro Studies:** Concentrations ranging from 10 nM to 1 μM are commonly employed to assess vasodilatory, anti-inflammatory, or cytoprotective effects in cell-based assays. Optimization of dosing and exposure time is recommended based on specific experimental endpoints.
- **In Vivo Studies:** Dosing regimens vary depending on the animal model and desired pharmacodynamic outcomes. Intravenous or intraperitoneal administration is preferred for systemic effects, with doses typically in the range of 0.1–10 μg/kg (Ishimitsu et al., 1994 Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 20 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11584406